Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 29,718 shares at $103.10 ($3.1M) on 2024-04-17, disclosed to the SEC on 2024-04-19.
Scheduled sale ($3.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $103.10 | 8,243 | $850K | 27.7% |
| 2 | $103.10 | 8,243 | $850K | 27.7% |
| 3 | $103.69 | 6,475 | $671K | 21.9% |
| 4 | $103.69 | 6,475 | $671K | 21.9% |
| 5 | $104.49 | 282 | $29K | 1.0% |
| Total | $103.37 avg | 29,718 |
| $3.1M |
| 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |